FCGRT and myasthenia gravis: A meta-analysis found that anti-FcRn has an advantage in improving the QMG score than complement treatments in patients with generalized MG, and they also proposed the high probability of efgartigimod and rozanolixizumab being the most effective treatment in generalized MG (45).